A Phase 2, Open-label, Randomized, Parallel Group, Controlled Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus-Positive, Non-Squamous, Non-Small Cell Lung Carcinoma Following First-Line Induction Chemotherapy
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2016
At a glance
- Drugs Axalimogene filolisbac (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Advaxis
- 17 Jun 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2019.
- 17 Jun 2016 Planned initiation date changed from 1 Jan 2016 to 1 Dec 2016.
- 30 Dec 2015 Planned initiation date changed from 1 Nov 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.